Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Toxicological Effects
  • Genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Belgium: Frenactil; Germany: Benperidol, Glianimon; Greece: Glianimon; Luxembourg: Frenactil; Netherlands: Frenactil; UK: Anquil.

Drug combinations


Benperidol: C~22~H~24~FN~3~O~2~. Mw: 381.44. (1) 2H-Benzimidazol-2-one, 1-[1-[4-fluorophenyl)-4-oxo-butyl]-4-piperidinyl]-1,3-dihydro-; (2) 1-{1-[3-(p-Fluorobenzoyl)propyl]-4-piperidinyl}-2-benximidazolinone. CAS-2062-84-2 (1962).

Pharmacologic Category

Antipsychotics; Butyrophenones. Neuroleptic. (ATC-Code: N05AD07).

Mechanism of action

Benperidol is a butyrophenone antipsychotic which blocks postsynaptic mesolimbic dopaminergic D~1~ and D~2~ receptors in the brain. It depresses the release of hypothalamic and hypophyseal hormones. It is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.

Therapeutic use

For the control of deviant anti-social sexual behaviour. In some countries benperidol is used for treatment of psychotic conditions.

Pregnancy and lactiation implications

Not recommended during pregnancy or lactation.

Unlabeled use


Comatose states. Patients with extrapyramidal symptoms. CNS depression. Hypersensitivity to any of the ingredients of benperidol or other butyrophenones. Depressive disorders or Parkinson’s disease.

Warnings and precautions

Acute withdrawal symptoms, including nausea, vomiting and insomnia, have very rarely been described after abrupt cessation of high doses of antipsychotic drugs. Relapse may also occur and gradual withdrawal is advisable. Caution is advised in liver disease, renal failure, cardiovascular disease, epilepsy, and conditions predisposing to epilepsy and convulsions. An approximately 3-fold increased risk of cerebrovascular adverse events has been seen in randomized placebo-controlled clinical trials in the dementia population with some atypical antipsychotics. The mechanism for this increased risk is not known. Benperidol should be used with caution in risk factors for stroke. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine as it contains lactose. As with other neuroleptics, cases of QT interval prolongation may occur. Absence of the following risk factors for onset of this type of arrhythmia should be verified prior to administration: cardiac disease, family history of sudden death and/or QT prolongation, uncorrected electrolyte disturbances, history of QT interval prolongation, ventricular arrhythmias or torsade de pointes. Concomitant neuroleptics should be avoided.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart